Compare ASYS & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASYS | MOLN |
|---|---|---|
| Founded | 1981 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 158.9M |
| IPO Year | 2006 | 2021 |
| Metric | ASYS | MOLN |
|---|---|---|
| Price | $13.19 | $4.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 271.8K | 1.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $79,364,000.00 | N/A |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $18.75 | $285.71 |
| P/E Ratio | $1,295.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $3.36 |
| 52 Week High | $18.59 | $5.36 |
| Indicator | ASYS | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 58.41 |
| Support Level | $11.60 | $3.50 |
| Resistance Level | $13.26 | $5.36 |
| Average True Range (ATR) | 0.74 | 0.18 |
| MACD | 0.11 | -0.01 |
| Stochastic Oscillator | 59.17 | 54.95 |
Amtech Systems Inc provides equipment, consumables and services for semiconductor device packaging, wafer production and device fabrication. Its products are used to fabricate and package GPUs for AI applications, SiC and Si power devices, and other optical, analog and digital devices, and are sold to semiconductor packaging, electronic assembly and device fabrication companies. It operates through two segments: Thermal Processing Solutions, which includes conveyorized reflow equipment, high-temperature conveyorized furnaces and diffusion furnaces with maximum revenue; and Semiconductor Fabrication Solutions, which includes consumables, equipment and services for wafer polishing, dicing and cleaning. The majority of revenue is derived from the United States.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.